Jazz Pharmaceuticals plc (JAZZ) saw its stock increase following the announcement of record second-quarter revenue and an upward revision of its full-year guidance. The positive performance was primarily attributed to the company's robust oncology portfolio.
Jazz Pharmaceuticals Stock Rises on Strong Q2 Revenue and Upbeat Outlook
JazzPharmaceuticalsEarningsOncologyHealthcareSectorStockPerformance
